Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gocatamig - Harpoon Therapeutics/Daiichi Sankyo Company

Next Previous
Search
Drug Profile

Gocatamig - Harpoon Therapeutics/Daiichi Sankyo Company

Alternative Names: DS-3280; HPN-328; MK-6070

Latest Information Update: 16 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harpoon Therapeutics
  • Developer Daiichi Sankyo Company; Harpoon Therapeutics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

  • 01 Mar 2025 Phase-I/II clinical trials in Small cell lung cancer (Second-line therapy or greater, Combination therapy) in Israel (IV) (NCT06780137)
  • 01 Mar 2025 Phase-I/II clinical trials in Small cell lung cancer (Second-line therapy or greater, Monotherapy) in Israel (IV) (NCT06780137)
  • 21 Jan 2025 Merck Sharp & Dohme plans a phase I/II trial for Small cell lung cancer (Second-line therapy or greater, Late-stage disease) in February 2025 (IV, Infusion) (NCT06780137)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top